Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497799 | 0.89 | TSPO (0.71) | TSPOSMN1; SMN2MAPTTP53KDM4E | |
| SCHEMBL22082635 | 0.89 | TSPO (0.80) | TSPOSMN1; SMN2MAPTTP53POLB | |
| SCHEMBL7750505 | 0.89 | TSPO (0.61) | TSPOSMN1; SMN2MAPTTP53KDM4E | |
| SCHEMBL197375 | 0.88 | TSPO (1.00) | TSPOMAPT | |
| SCHEMBL7501779 | 0.82 | TSPO (0.55) | TSPOSMN1; SMN2MAPTTP53KDM4E | |
| SCHEMBL17959423 | 0.79 | TSPO (0.83) | TSPOPOLB | |
| SCHEMBL4842381 | 0.79 | TSPO (0.83) | TSPO | |
| SCHEMBL5744887 | 0.79 | TSPO (0.66) | TSPOSMN1; SMN2POLB | |
| SCHEMBL5745978 | 0.79 | TSPO (0.84) | TSPOMAPT | |
| SCHEMBL5746627 | 0.79 | TSPO (0.66) | TSPOSMN1; SMN2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170160287-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI (FR) | 2017-06-08 | — | — | US | disclosed |
| EP-2349352-B1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | SANOFI SA (FR) | 2013-12-25 | — | — | EP | disclosed |
| US-20120039816-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI-AVENTIS (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2181717-A1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | Sanofi-Aventis (FR) | 2010-05-05 | — | — | EP | disclosed |
| EP-1000063-B1 | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SYNTHELABO (FR) | 2002-10-23 | — | — | EP | disclosed |
| US-6262045-B1 | TREATMENT OF ANXIETY; SLEEP DISORDER; EPILEPSY; SPASTICITY; MUSCLE CONTRACTURE OR AN EXTRAPYRAMIDAL SYNDROM; INDUCING OR MAINTAINING ANAESTHESIA | SANOFI-SYNTHELABO (FR) | 2001-07-17 | — | — | US | disclosed |